<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798572</url>
  </required_header>
  <id_info>
    <org_study_id>Ms: 7-12-2022</org_study_id>
    <nct_id>NCT05798572</nct_id>
  </id_info>
  <brief_title>Pre-Op Sildosine and Ureteral Dilation During F-URS</brief_title>
  <official_title>Is Preoperative Sildosine Adminstration Faciltate Ureteral Diltation During Flexible Ureterorenoscopy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We proposed that silodosin administration preoperatively may facilitate ureteral access&#xD;
      sheath (UAS) placement prior to flexible ureteroscopy (F-URS) and decrease the incidence of&#xD;
      ureteric injury in some difficult cases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Urolithiasis is a common urological disorder in the world and has a significant effect on the&#xD;
      global health system. The goal of treatment is to achieve the highest stone-free rate (SFR)&#xD;
      with the least invasive. PerÂ¬cutaneous nephrolithotomy and flexible ureterorenoscopy (F-URS)&#xD;
      are the two main minimally invasive procedures for the treatment of upper urinary tract&#xD;
      stones.&#xD;
&#xD;
      The challenging step in flexible ureterorenoscopy (F-URS) is ureteroscopic access sheath&#xD;
      (UAS) placement, which facilitates fast and safe access to the ureter and collecting system;&#xD;
      improves visibility; reduces the risk of infection by reducing intrarenal pressure. However,&#xD;
      in some cases, the acute ureteric injury may occur during ureteroscopic access sheath (UAS)&#xD;
      placement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2023</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Entrance to bladder time (ETBT)</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Entrance to bladder time (ETBT) will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Entrance to ureteric orifice time (ETUOT)</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Entrance to ureteric orifice time (ETUOT) will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Application of access sheath time (AAST)</measure>
    <time_frame>Intraoperatively</time_frame>
    <description>Application of access sheath time (AAST) will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>FURS</condition>
  <condition>Ureteral Dilatation</condition>
  <condition>Sildosine</condition>
  <arm_group>
    <arm_group_label>Sildosin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>including 67 patients for whom flexible ureteroscopy (F-URS) will be done with a preoperative daily intake of 8 mg silodosin for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Silodosin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>including 67 patients for whom flexible ureteroscopy (F-URS) will be done without silodosin intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildosin group</intervention_name>
    <description>Patients in this group will have flexible ureteroscopy (F-URS) with preoperative daily uptake of 8 mg silodosin for one week.</description>
    <arm_group_label>Sildosin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-Silodosin group</intervention_name>
    <description>Patients in this group will have flexible ureteroscopy (F-URS) without silodosin uptake</description>
    <arm_group_label>Non-Silodosin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Upper ureteric stone or stone kidney (with stone burden equal to or less than 20mm).&#xD;
&#xD;
          -  2. Non stented.&#xD;
&#xD;
          -  Age (Above 18 years old).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic renal insufficiency.&#xD;
&#xD;
          -  Uncorrected coagulopathy.&#xD;
&#xD;
          -  Previous open (lumber or ureteric) surgery.&#xD;
&#xD;
          -  Active urinary tract infection unless treated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tamer Diab, MD</last_name>
    <phone>01003583264</phone>
    <phone_ext>+2</phone_ext>
    <email>Tamer.diab@fmed.bu.edu.eg</email>
  </overall_contact>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 23, 2023</study_first_submitted>
  <study_first_submitted_qc>March 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 17, 2023</last_update_submitted>
  <last_update_submitted_qc>April 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Tamer Abd El-Wahab Diab</investigator_full_name>
    <investigator_title>Lecturer of Urology, Faculty of Medicine, Benha University, Benha, Egypt</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dilatation, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study will be available under a reasonable request from the corresponding author.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>One year after the end of the study.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

